Niagen Bioscience publishes Q3 2026 earnings call transcript
NAGE•Niagen Bioscience reported third-quarter 2026 net sales of $27.2 million and a net loss of $1.2 million, or $0.01 per diluted share. Management expects fourth-quarter revenue to improve sequentially and plans to complete NB4168 IND-enabling studies in early 2027.
1. Quarterly results and outlook
Niagen Bioscience's third-quarter 2026 earnings call featured CEO Robert N. Fried and CFO Ozan Pamir. Net sales totaled $27.2 million, while the net loss was $1.2 million, or $0.01 per diluted share. Management expects fourth-quarter revenue to improve sequentially, with increased marketing spending supporting brand campaigns, distribution and new products.
2. Development and cost plans
The company targets completing NB4168's IND-enabling studies in early 2027 and plans first-in-human testing that year, subject to regulatory clearance. Commercialization of lower-cost NR malate is expected in early 2027; management expects initial ingredient cost reductions, with more significant savings thereafter.
